Cite
HARVARD Citation
Yao, J. et al. (n.d.). 5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study. European journal of cancer. pp. S709-S710. [Online].